Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Brainstorm Cell Therapeutics Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 47 | 48 | +1 |
| Shares | 4.04M | 12.2M | +8.19M (+202.7%) |
| Value | $2.19M | $4.09M | +$1.90M (+86.5%) |
New holders (7)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 7,917,653 | $2.68M | 0.07% |
| Two Sigma Securities, LLC | 102,016 | $34.5K | 0.00% |
| Virtu Financial LLC | 49,586 | $17.0K | 0.00% |
| Sanctuary Advisors, LLC | 17,210 | $9.20K | 0.00% |
| LPL Financial LLC | 10,052 | $3.40K | 0.00% |
| Activest Wealth Management | 7,080 | $2.40K | 0.00% |
| Northwestern Mutual Wealth Management Co | 161 | $55 | 0.00% |
Sold out (6)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Gsa Capital Partners LLP | 111,234 | $63.0K |
| Kingswood Wealth Advisors, LLC | 81,050 | $45.8K |
| Susquehanna International Group, LLP | 26,544 | $15.0K |
| Socha Financial Group, LLC | 12,380 | $6.99K |
| Cypress Capital Management LLC (WY) | 10,000 | $5.65K |
| CoreCap Advisors, LLC | 133 | $75 |